跳至主要内容
临床试验/NCT06772974
NCT06772974尚未招募不适用

Comparison of Tablet Ginger Versus Tablet Doxylamine Succinate in Control of Nausea and Vomiting in Pregnancy

Nawaz Sharif Medical College1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2025年1月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
66
试验地点
1
主要终点
Reduction in Nausea and Vomiting based on Pregnancy-Unique Quantification of Emesis Score

研究概览

简要总结

Nausea and vomiting are common GI symptoms of pregnancy. Multiple managing options have been used for NVP. Doxylamine succinate is used as first line treatment for NVP despite that alternative modalities such as ginger extracts and tablets is being explored.

This RCT will be conducted after taking ethical approval and informed consent, in Department of Gynecology, Aziz Bhatti Shaheed teaching hospital, Gujrat. Patients will be divided into two equal groups. One group will receive tablet ginger while other group will receive Doxylamine succinate tablets. Baseline PUQE score (3- 15 point scale) over 24 hour will be noted according to symptoms of nausea and vomiting following 7 days of treatment and then at 2nd and 3rd week. Comparison of the change in the severity of nausea from baseline scores (Post-therapy PUQE score - base line scores) in both groups will be considered for results.

详细描述

Nausea and vomiting are the most common gastrointestinal symptoms of pregnancy. Several treatments have been used for managing NVP. Multiple medications have been used in treatment of NVP. Doxylamine plus pyridoxine is used as first line therapy for NVP. However treatment with alternative medications including ginger extracts and tablets is being explored.

This randomized control trial will be conducted after taking ethical approval and informed consent, in Department of Gynecology, Aziz Bhatti Shaheed teaching hospital, Gujrat. Total 66pregnant females will be enrolled. Demographical data will be recorded. Patients will be divided into two groups (n= 33 in each group). Group A will receive tablet ginger (Zingiber officinale 250mg orally four times daily for 21 days). Group B will receive Doxylamine succinate tablets (10 mg orally, three times daily for 21 days). Baseline PUQE score (3- 15 point scale) over 24 hour will be noted according to symptoms of nausea and vomiting following 7 days of treatment and then at 2nd and 3rd week. Comparison of the change in the severity of nausea from baseline scores (Post-therapy PUQE score - base line scores) in both groups.

Data will be analyzed via SPSS version 25.0. Independent t test and Chi-square test will be used for comparison of the variables between the groups. A paired t test will be used to assess the mean difference in PUQE score within each group (baseline to follow-up). A p-value ≤ 0.05 will be considered as significant. This study aims to compare the efficacy of these two interventions in controlling or reducing the NVP in pregnant women particularly in our local population and will also explore whether ginger or Doxylamine succinate is better in terms of safety. The study will have both theoretical and practical implications provides evidence based clinical data regarding effective NVP treatment in our local population. However, the study will be limited to single center and small sample size.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 49 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women age>18 years
  • 5 to 8weeks of gestation and 8+1to11weeks
  • Attending OPD with signs and symptoms of nausea and vomiting with ultrasound confirmed pregnancy
  • 1st and 2nd gravida
  • Patients who will give consent

排除标准

  • Patients were hospitalized for Hyperemesis Gravidarum
  • Medical disorders like Diabetes Mellitus, Hepatic, Gastric, Pancreatic, Pyelonephritis, Thyroid and Psychological Disorder
  • Patients not responding to treatment after 1week will be excluded
  • Patients who will not give consent

研究组 & 干预措施

Ginger Group

Experimental

Ginger

干预措施: Ginger (Dietary Supplement)

Doxylamine Group

Active Comparator

Tab. Doxylamine Succinate USP

干预措施: Doxylamine Succinate USP (Drug)

结局指标

主要结局

Reduction in Nausea and Vomiting based on Pregnancy-Unique Quantification of Emesis Score

时间窗: 21 Days

improvement in Nausea and reduction in Vomiting based on Pregnancy-Unique Quantification of Emesis score. This score depicts the severity of emesis. Mild 4-6 moderate 7-12 and severe emesis is considered when score is more than 13. The primary efficacy endpoint will be the change from baseline in PUQE score after 21 days (± 1 day).

次要结局

  • Side Effects of Treatment(21 Days)

研究者

发起方
Nawaz Sharif Medical College
申办方类型
Other
责任方
Principal Investigator
主要研究者

Zunaira Pervez

Post Gradute Resident

Nawaz Sharif Medical College

研究点 (1)

Loading locations...

相似试验